{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:18:44Z","timestamp":1790666324320,"version":"4.1.0"},"reference-count":13,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1128\/aac.02093-13","type":"journal-article","created":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T04:07:25Z","timestamp":1383624445000},"page":"624-625","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":56,"title":["First Three Neisseria gonorrhoeae Isolates with High-Level Resistance to Azithromycin in Sweden: a Threat to Currently Available Dual-Antimicrobial Regimens for Treatment of Gonorrhea?"],"prefix":"10.1128","volume":"58","author":[{"given":"Magnus","family":"Unemo","sequence":"first","affiliation":[{"name":"WHO Collaborating Centre for Gonorrhoea and other STIs, Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, \u00d6rebro University Hospital, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Golparian","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Gonorrhoea and other STIs, Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, \u00d6rebro University Hospital, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Hellmark","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Gonorrhoea and other STIs, Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, \u00d6rebro University Hospital, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.63"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.117"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt034"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.176575"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt017"},{"key":"e_1_3_1_7_2","first-page":"590","article-title":"Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer recommended for treatment of gonococcal infections","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","unstructured":"Centers for Disease Control and Prevention. 2012. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer recommended for treatment of gonococcal infections. MMWR Morb. Mortal. Wkly. Rep. 61:590\u2013594.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0956462412472837"},{"key":"e_1_3_1_9_2","volume-title":"Treatment of gonorrhoea in an era of emerging cephalosporin resistance and results of a randomized trial of new potential treatment options","author":"Kirkcaldy RD","year":"2013","unstructured":"KirkcaldyRD. 2013. Treatment of gonorrhoea in an era of emerging cephalosporin resistance and results of a randomized trial of new potential treatment options, abstr SO8.1. STI & AIDS World Congress 2013, Vienna, Austria, 14 to 17 July 2013."},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp098"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.177.14.4162-4165.1995"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2468"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00036-12"},{"key":"e_1_3_1_14_2","volume-title":"A phase 2 study to evaluate the efficacy and safety of single dose solithromycin (CEM-101) for the treatment of patients with uncomplicated urogenital gonorrhoea","author":"Hook E","year":"2013","unstructured":"HookEIIIOldachDJamiesonBClarkKFernandesP. 2013. A phase 2 study to evaluate the efficacy and safety of single dose solithromycin (CEM-101) for the treatment of patients with uncomplicated urogenital gonorrhoea, abstr O274. European Congress of Clinical Microbiology and Infectious Disease, Berlin 2013, Berlin, Germany."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02093-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02093-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:40:18Z","timestamp":1645483218000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02093-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1128\/AAC.02093-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.02093-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"2014-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}